1. Home
  2. AMTB vs IVA Comparison

AMTB vs IVA Comparison

Compare AMTB & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$24.67

Market Cap

894.1M

Sector

Finance

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$3.47

Market Cap

883.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
IVA
Founded
1979
2011
Country
United States
France
Employees
N/A
77
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
894.1M
883.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
AMTB
IVA
Price
$24.67
$3.47
Analyst Decision
Buy
Strong Buy
Analyst Count
3
10
Target Price
$23.67
$16.20
AVG Volume (30 Days)
223.2K
935.4K
Earning Date
04-23-2026
03-30-2026
Dividend Yield
1.57%
N/A
EPS Growth
386.36
N/A
EPS
0.44
N/A
Revenue
N/A
N/A
Revenue This Year
$8.29
N/A
Revenue Next Year
$7.67
$751.20
P/E Ratio
$55.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.62
$2.94
52 Week High
$24.38
$7.98

Technical Indicators

Market Signals
Indicator
AMTB
IVA
Relative Strength Index (RSI) 66.64 31.77
Support Level $21.68 N/A
Resistance Level N/A $4.67
Average True Range (ATR) 0.62 0.21
MACD 0.15 -0.00
Stochastic Oscillator 97.21 2.02

Price Performance

Historical Comparison
AMTB
IVA

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: